CCR2 and prostate neoplasm: HFD can induce prostate tumor growth through a large suite of chemical signaling pathways, such as the activation of IL6/pSTAT3 or MCP-1/CCR2 signalings, or through the inhibition of tumor suppressor gene PTEN [21–23].